Australia Stock Exchange release from NEUROTECH INTERN : Preclinical Success with Targeted Combination Therapies
30/11/2021 22:00
Australia Stock Exchange release from NEUROTECH INTERN NTI.AX : Preclinical Success with Targeted Combination Therapies
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt